Independent Financial Group LLC Invests $755,000 in Globus Medical, Inc. $GMED

Independent Financial Group LLC acquired a new position in shares of Globus Medical, Inc. (NYSE:GMED) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 8,760 shares of the medical device company’s stock, valued at approximately $755,000.

A number of other hedge funds have also recently made changes to their positions in GMED. Annex Advisory Services LLC purchased a new stake in shares of Globus Medical during the fourth quarter valued at about $20,572,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Globus Medical by 71,618.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after buying an additional 715,470 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Globus Medical by 510.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 266,532 shares of the medical device company’s stock worth $23,271,000 after buying an additional 222,841 shares during the last quarter. Lecap Asset Management Ltd. purchased a new position in shares of Globus Medical in the 4th quarter worth approximately $1,203,000. Finally, Artemis Investment Management LLP grew its position in shares of Globus Medical by 43.7% in the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock worth $64,487,000 after buying an additional 224,587 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 18.38% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GMED has been the subject of a number of analyst reports. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Stifel Nicolaus cut their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Royal Bank Of Canada reduced their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Truist Financial decreased their price objective on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Finally, Needham & Company LLC raised their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $103.75.

Globus Medical Stock Down 0.0%

GMED stock opened at $75.99 on Wednesday. The firm has a 50 day moving average of $79.82 and a 200 day moving average of $86.29. The stock has a market capitalization of $10.31 billion, a PE ratio of 17.67, a price-to-earnings-growth ratio of 1.57 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.